Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Yale University
New Haven, Estados UnidosPublicacions en col·laboració amb investigadors/es de Yale University (10)
2023
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569
2021
-
A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy
Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
2020
-
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Nature Medicine, Vol. 26, Núm. 5, pp. 688-692
2019
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12
-
Immunotherapy in non-small cell lung cancer: Facts and hopes
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4592-4602
2017
-
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 389, Núm. 10064, pp. 67-76
-
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study
Annals of Oncology, Vol. 28, Núm. 12, pp. 3044-3050